Responses of Myocardial Ischemia to Escitalopram Treatment

• Status: Completed
• Trial end date: 2011-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Depression is commonly seen in patients with cardiovascular disorders. In recent studies it has been shown that mild to moderate depression symptoms were associated with increased likelihood of mental stress-induced myocardial ischemia (MSIMI), which is a risk factor of poor cardiac outcome. In this project, the investigators aim to assess the treatment of mental stress-induced myocardial ischemia in ischemic heart disease patients with mild to moderate depressive symptoms. This study is a six-week double-blind placebo controlled study to examine the effects of escitalopram on mental stress-induced myocardial ischemia. This study will look to show that patients with ischemic heart disease who are treated with escitalopram will exhibit a significant improvement of MSIMI at the end of week 6 compared to patients receiving placebo.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Duke University
• Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
• Treatments: Citalopram; Dexetimide

Criteria

Inclusion Criteria:

• Age 21 or greater, less than 90

• Stable ischemic heart disease

Exclusion Criteria:

• Recent myocardial infarction, coronary artery bypass graft surgery, or other revascularization procedures (less than 3 months ago)

• Left ventricular ejection fraction(LVEF) < 15% measured by echocardiography, radionuclide ventriculography (RNV), or cardiac catheterization

• Life threatening arrhythmia or arrhythmia interrupting the interpretation of ischemia

• Unable to withdraw from anti-anginal medications during ischemic assessment phase

• Unable to perform exercise testing

• Pregnancy

• Current or previous history of bipolar disorder, cyclothymia, schizophrenia, schizoaffective or schizophreniform disorder, or other psychotic disorders

• Active suicidal ideation

• Current substance abuse or history of substance abuse in the previous 6 months

• Significant cardiac, pulmonary, metabolic, renal, hepatic disease, or malignancy, interfering with patient's participation in this study

• Seizure (history and/or present) with/without treatment

• Currently taking antidepressants that cannot be discontinued